The stock of Prime Medicine Inc (PRME) has gone down by -30.17% for the week, with a -34.21% drop in the past month and a -61.89% drop in the past quarter. The volatility ratio for the week is 15.53%, and the volatility levels for the past 30 days are 11.54% for PRME. The simple moving average for the last 20 days is -28.95% for PRME’s stock, with a simple moving average of -64.89% for the last 200 days.
Is It Worth Investing in Prime Medicine Inc (NASDAQ: PRME) Right Now?
The 36-month beta value for PRME is at 2.15. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PRME is 51.92M, and currently, shorts hold a 37.38% of that float. The average trading volume for PRME on April 10, 2025 was 1.24M shares.
PRME) stock’s latest price update
Prime Medicine Inc (NASDAQ: PRME) has experienced a rise in its stock price by 8.70 compared to its previous closing price of 1.15. However, the company has seen a fall of -30.17% in its stock price over the last five trading days. globenewswire.com reported 2025-04-07 that MONTREAL, April 07, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to the termination of the forbearance agreements Roynat Inc. (“Roynat”), Financement Agricole Canada (“FAC”) and Banque Canadienne Impériale de Commerce (“CIBC” and together with Roynat and FAC, the “Creditors”) “principal creditors” have filed an application pursuant to Section 243 of the Bankruptcy and Insolvency Act (Canada) with the Superior Court, District of Montréal (the “Application”), to have a receiver appointed with respect to the assets of Prime’s wholly-owned subsidiary, Triani Canada Inc (“Triani”).
Analysts’ Opinion of PRME
Many brokerage firms have already submitted their reports for PRME stocks, with JMP Securities repeating the rating for PRME by listing it as a “Mkt Outperform.” The predicted price for PRME in the upcoming period, according to JMP Securities is $10 based on the research report published on December 10, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PRME reach a price target of $10. The rating they have provided for PRME stocks is “Buy” according to the report published on May 20th, 2024.
Citigroup gave a rating of “Buy” to PRME, setting the target price at $10 in the report published on May 16th of the previous year.
PRME Trading at -44.15% from the 50-Day Moving Average
After a stumble in the market that brought PRME to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.89% of loss for the given period.
Volatility was left at 11.54%, however, over the last 30 days, the volatility rate increased by 15.53%, as shares sank -34.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.83% lower at present.
During the last 5 trading sessions, PRME fell by -30.17%, which changed the moving average for the period of 200-days by -79.13% in comparison to the 20-day moving average, which settled at $1.7593. In addition, Prime Medicine Inc saw -57.19% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PRME
Current profitability levels for the company are sitting at:
- -4.97 for the present operating margin
- 0.99 for the gross margin
The net margin for Prime Medicine Inc stands at -4.81. The total capital return value is set at -0.78. Equity return is now at value -136.88, with -48.54 for asset returns.
Based on Prime Medicine Inc (PRME), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -3.01.
Currently, EBITDA for the company is -202.47 million with net debt to EBITDA at 0.72. When we switch over and look at the enterprise to sales, we see a ratio of 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.58.
Conclusion
In conclusion, Prime Medicine Inc (PRME) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
